REVIEW

Top 100 Cited Articles in Thyroid Cancer: A Bibliometric Analysis
Tiroid Kanserinde En Fazla Atıf Alan 100 Makale: Bibliyometrik Bir Analiz
Received Date : 25 Apr 2021
Accepted Date : 02 Jun 2021
Available Online : 21 Jun 2021
Doi: 10.25179/tjem.2021-84035 - Makale Dili: EN
Turk J Endocrinol Metab. 2021;25:318-336
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Objective: To identify and analyze the 100 most cited articles on thyroid cancer since 1975, thus, allowing their easy access for researchers in this field. Material and Methods: This study is a bibliometric analysis of research publications acquired from the Web of Science database. We evaluated the first 100 articles receiving the most citations in the field of thyroid cancer since 1975. Then, all research publications were compiled using journal information into different categories based on the study type, country, research centers, authors, and publication dates. All data were reported as percentages, numbers, and graphs. Results: In this study, we listed 8,608 full-length English-language articles. Our findings showed that the most cited article received 4,325 citations to date, while the Journal of Clinical Endocrinology Metabolism, a Thyroid journal, received the most number of citations (n:6531), publishing seventeen of the articles from our study. Also, thirty-two articles were from the field of oncology. The country with the most number of publications was the United States of America (n=70) in the years 2005, 2008, and 2009 (n=8). Conclusion: It is essential to acknowledge the top-cited articles in thyroid cancer since they contain essential information, research, and advances in its treatment. Our analysis of the first 100 articles included the most important papers with the most significant impact on thyroid cancer research. In our list, we acknowledged the most productive authors and institutions along with their research articles.
ÖZET
Amaç: Bu makaledeki amacımız, 1975 yılından bu yana tiroid kanseri ile ilgili en çok atıf alan 100 makaleyi belirlemek ve analiz etmek, böylece bu alandaki araştırmacılara kolay erişim sağlamaktır. Gereç ve Yöntemler: Bu çalışma, Web of Science veri tabanından elde edilen araştırma yayınlarının bibliyometrik analizidir. 1975 yılından bu yana tiroid kanseri alanında en çok atıf alan ilk 100 makaleyi değerlendirdik. Ardından tüm makaleler, dergi bilgileri kullanılarak, çalışma türü, çalışmanın yapıldığı ülke, çalışmanın yapıldığı araştırma merkezi, makalenin yazarları ve yayın tarihlerine göre farklı kategorilerde değerlendirildi. Tüm veriler yüzde, sayı ve grafik olarak rapor edildi. Bulgular: Bu çalışmada, 8.608 tam uzunlukta İngilizce makale listelendi. Bulgularımız, bugüne kadar en çok atıf alan makalenin 4.325 atıf aldığını, bir tiroid dergisi olan Journal of Clinical Endocrinology Metabolism'in ise en fazla atıf aldığını (n:6531) ve konumuzla ilgili 17 makale yayımladığını gösterdi. Ayrıca onkoloji alanından 32 makale vardı. 2005, 2008 ve 2009 yıllarında (n=8) en fazla yayına sahip ülke Amerika Birleşik Devletleri (n=70) olmuştur. Sonuç: Tiroid kanserinde en çok atıf alan makaleleri, temel bilgileri, araştırmaları ve tedavisindeki ilerlemeleri içerdiği için bilmek önemlidir. İlk 100 makaleye ilişkin analizimiz, tiroid kanseri araştırmaları üzerinde en önemli etkiye sahip en önemli makaleleri içeriyordu. Listemizde en verimli yazarları ve kurumları araştırma makaleleriyle birlikte seçtik.
KAYNAKLAR
  1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Casta-eda- Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1:505-527. Erratum in: JAMA Oncol. 2015;1: 690. Jonas, Jost [corrected to Jonas, Jost B]; Tillman, Taavi [corrected to Tillmann, Taavi]. [Crossref] [PubMed] [PMC] 
  2. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72. [Crossref] [PubMed] [PMC] 
  3. Wrafter PF, Connelly TM, Khan J, Devane L, Kelly J, Joyce WP. The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. Surgeon. 2016;14:327-336. [Crossref] [PubMed] 
  4. Uysal E. Top 100 cited classic articles in breast cancer research. Eur J Breast Health. 2017;13:129-137. [Crossref] [PubMed] [PMC] 
  5. Manuel Vázquez A, Latorre Fragua R, López Marcano A, Ramiro Pérez C, Arteaga Peralta V, de la Plaza-Llamas R, Ramia JM. The top 100: A review of the most cited articles in Surgery. Cir Esp (Engl Ed). 2019; 97:150-155. English, Spanish. [Crossref] [PubMed] 
  6. Ahmad SS, Ahmad SS, Kohl S, Ahmad S, Ahmed AR. The hundred most cited articles in bariatric surgery. Obes Surg. 2015;25:900-909. [Crossref] [PubMed] 
  7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26:1-133. [Crossref] [PubMed] [PMC] 
  8. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park DJ. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118: 1764-1773. [Crossref] [PubMed] 
  9. Ellul T, Bullock N, Abdelrahman T, Powell AG, Witherspoon J, Lewis WG. The 100 most cited manuscripts in emergency abdominal surgery: A biblio metric analysis. Int J Surg. 2017;37:29-35. [Crossref] [PubMed] 
  10. O'Sullivan K, Hurley JP. The 100 most cited publications in transplantation. Ann Transplant. 2014; 19:436-443. [Crossref] [PubMed] 
  11. Campbell FM. National bias: a comparison of citation practices by health professionals. Bull Med Libr Ass oc. 1990;78:376-382. [Crossref] [PubMed] [PMC] 
  12. Link AM. US and non-US submissions: an analysis of reviewer bias. JAMA. 1998;280:246-247. [Crossref] [PubMed] 
  13. Shuaib W, Khan MS, Shahid H, Valdes EA, Alweis R. Bibliometric analysis of the top 100 cited cardiovascular articles. Am J Cardiol. 2015;115:972-981. [Crossref] [PubMed] 
  14. Baltussen A, Kindler CH. Citation classics in critical care medicine. Intensive Care Med. 2004;30:902-910. [Crossref] [PubMed] 
  15. Tam WW, Wong EL, Wong FC, Hui DS. Citation classics: Top 50 cited articles in 'respiratory system'. Respirology. 2013;18:71-81. [Crossref] [PubMed] 
  16. Heldwein FL, Rhoden EL, Morgentaler A. Classics of urology: a half century history of the most frequently cited articles (1955-2009). Urology. 2010;75:1261-1268. [Crossref] [PubMed] 
  17. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167. [Crossref] [PubMed] 
  18. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428. Erratum in: Am J Med 1995;98:215. [Crossref] [PubMed] 
  19. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-772. [Crossref] [PubMed] [PMC] 
  20. Wells Jr SA, Robinson BG, Gagel RF, Dralle H,Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of clinical oncology. 2012;30:134.[Crossref]  [PubMed]  [PMC] 
  21. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The lancet oncology. 2012;13:897-905. [Crossref] 
  22. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. [Crossref] [PubMed] 
  23. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pe-a C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328. [Crossref] [PubMed] [PMC] 
  24. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology. 2008;26:4714.[Crossref]  [PubMed]  [PMC] 
  25. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology. 2009;27: 1675. [Crossref]  [PubMed]  [PMC] 
  26. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely Jr PE, Vasko VV. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology. 2010;28:2323.[Crossref]  [PubMed]  [PMC] 
  27. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hes sel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639-3646. Erratum in: J Clin Oncol. 2014;32:1864. [Crossref] [PubMed] [PMC] 
  28. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. [Crossref] [PubMed] [PMC] 
  29. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology. 2008;26:4708.[Crossref]  [PubMed]  [PMC] 
  30. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine. 2013;368:623-632.[Crossref]  [PubMed]  [PMC] 
  31. Scollo C, Baudin E, Travagli J-P, Caillou B, Bellon N, Leboulleux S, Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2003;88:2070-2075. [Crossref]  [PubMed] 
  32. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. The Journal of Clinical Endocrinology & Metabolism. 2004;89:163-168.[Crossref]  [PubMed] 
  33. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10- year follow-up study. The Journal of Clinical Endocrinology & Metabolism. 2008;93:682-687. [Crossref]  [PubMed] 
  34. Kang S-W, Jeong JJ, Yun J-S, Sung TY, Lee SC, Lee YS, Nam K-H, Chang HS, Chung WY, Park CS. Robot-assisted endoscopic surgery for thyroid cancer: experience with the first 100 patients. Surgical endoscopy. 2009;23:2399-2406.[Crossref]  [PubMed] 
  35. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-791. [Crossref] [PubMed] [PMC] 
  36. Elashoff M, Matveyenko AV, Gier B, Elashoff R, But-ler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gas-troenterology. 2011;141:150-156. [Crossref] [PubMed] [PMC] 
  37. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thak-ker RV, Watkinson J, Williams GR; British Thyroid As-sociation. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1122. [Crossref] [PubMed] 
  38. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton- Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493-1501. [Crossref] [PubMed] [PMC] 
  39. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive io-dine remnant ablation: using response to therapy va-riables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-1349. [Crossref] [PubMed] [PMC] 
  40. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331-4341. [Crossref] [PubMed] [PMC] 
  41. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Con-trol. 2009;20:525-531. [Crossref] [PubMed] [PMC] 
  42. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187-2195. [Crossref] [PubMed] 
  43. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381; discussion 381-4. [Crossref] [PubMed] [PMC] 
  44. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ri-card M, Benhamou E; Tumeurs de la Thyroïde Ref-ractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663-1673. [Crossref] [PubMed] 
  45. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Ro-senthal MS, Shah MH, Shaha AR, Tuttle RM; Ameri-can Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplas-tic thyroid cancer. Thyroid. 2012;22:1104-1139. [Crossref] [PubMed] 
  46. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89:1638-1644.[Crossref]  [PubMed]  [PMC] 
  47. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559-567; discussion 567-568. [Crossref] [PubMed] 
  48. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB,Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015;25:716-759. [Crossref] [PubMed] [PMC] 
  49. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31-42. [Crossref] [PubMed] 
  50. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E,Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005;97:724-732. [Crossref] [PubMed] 
  51. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Ca-bozantinib), an oral tyrosine kinase inhibitor, in pati-ents with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-2666. [Crossref] [PubMed] [PMC] 
  52. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156:2165-2172. [Crossref] [PubMed] 
  53. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H; European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349:1517-1525. [Crossref] [PubMed] 
  54. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718-2726. [Crossref] [PubMed] [PMC] 
  55. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309: 937-941.[Crossref]  [PubMed] 
  56. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674-1685. [Crossref] [PubMed] 
  57. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404.[Crossref]  [PubMed] 
  58. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472. [PubMed] 
  59. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22-28. [Crossref] [PubMed] 
  60. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058-1069. [Crossref] [PubMed] [PMC] 
  61. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken- Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946-954. [Crossref]  [PubMed] 
  62. Leenhardt L, Grosclaude P, Chérié-Challine L; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid no-dule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056-1060. [Crossref] [PubMed] 
  63. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A. The preva-lence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466-470; discussion 470-1.[Crossref]  [PubMed]  [PMC] 
  64. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr. A population-based casecontrol study of thyroid cancer. J Natl Cancer Inst. 1987;79:1-12. [PubMed] 
  65. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115:94-101. [Crossref] [PubMed] [PMC] 
  66. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am J Med. 1987;83:479-488. [Crossref] [PubMed] 
  67. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg. 1982;196:361-370. [Crossref] [PubMed] [PMC] 
  68. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-1170. [Crossref] [PubMed] 
  69. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refrac-tory differentiated thyroid cancer and metastatic me-dullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260-5268. [Crossref] [PubMed] [PMC] 
  70. Melillo RM, Castellone MD, Guarino V, De Falco V, Ci-rafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. The Journal of Clinical Investigation. 2016;126:1603-1603.[Crossref]  [PubMed]  [PMC] 
  71. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fu-gazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Na-kayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. Association between BRAF V600E muta-tion and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42-50. [Crossref] [PubMed] [PMC] 
  72. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid can-cer. J Clin Endocrinol Metab. 2013;98:E1852-1860. [Crossref] [PubMed] [PMC] 
  73. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Io-dine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492. [Crossref] [PubMed] 
  74. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: phe-ochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-783. [Crossref] [PubMed] [PMC] 
  75. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonas-son JG, Sigurdsson A, Bergthorsson JT, He H, Blon-dal T, Geller F, Jakobsdottir M, Magnusdottir DN, Matthiasdottir S, Stacey SN, Skarphedinsson OB, Helgadottir H, Li W, Nagy R, Aguillo E, Faure E, Prats E, Saez B, Martinez M, Eyjolfsson GI, Bjornsdottir US, Holm H, Kristjansson K, Frigge ML, Kristvinsson H, Gulcher JR, Jonsson T, Rafnar T, Hjartarsson H, Mayordomo JI, de la Chapelle A, Hrafnkelsson J, Thorsteinsdottir U, Kong A, Stefansson K. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009;41:460-464. [Crossref] [PubMed] [PMC] 
  76. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differen-tiated thyroid cancer-a quantitative radiation dosi-metric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1132-1136. [PubMed] 
  77. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlum-berger M. Ultrasound criteria of malignancy for cer-vical lymph nodes in patients followed up for differen tiated thyroid cancer. J Clin Endocrinol Metab. 2007; 92:3590-3594. [Crossref] [PubMed] 
  78. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin En-docrinol Metab. 2008;93:809-814. [Crossref] [PubMed] [PMC] 
  79. Morris LG, Sikora AG, Tosteson TD, Davies L. The in-creasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23:885-891. [Crossref] [PubMed] [PMC] 
  80. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Her-rero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini, ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226-3235. [Crossref] [PubMed] 
  81. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Mar-tins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-3801. [Crossref] [PubMed] 
  82. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007;31:895-904. [Crossref] [PubMed] 
  83. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested casecontrol study. Lancet. 2005;365:2014-2023.[Crossref]  [PubMed] 
  84. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91: 4070-4076. [Crossref] [PubMed] 
  85. Tucker MA, Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991;51:2885-2888. [PubMed] 
  86. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011; 21:125-134. [Crossref] [PubMed] [PMC] 
  87. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731-734. [Crossref] [PubMed] 
  88. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2- deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302. [Crossref] [PubMed] 
  89. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, de la Chapelle A. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A. 2009;106:1502-1505. [Crossref] [PubMed] [PMC] 
  90. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, Reading CC, Charboneau JW. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489-494; discussion 494-496. [Crossref] [PubMed] 
  91. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-10207. [Crossref] [PubMed] 
  92. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin le-vels in papillary thyroid cancer. Surgery. 2006; 140:1000-1005; discussion 1005-1007. [Crossref] [PubMed] 
  93. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175-178. [Crossref] [PubMed] 
  94. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562-1566. [Crossref] [PubMed] [PMC] 
  95. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, Maggiolini M. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol. 2006;70:1414-1423.[Crossref]  [PubMed] 
  96. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648-654. [PubMed] 
  97. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-1074. [Crossref] [PubMed] [PMC] 
  98. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999; 26:1547-1552. [Crossref] [PubMed] 
  99. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113. [Crossref] [PubMed] 
  100. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-515. [Crossref] [PubMed] 
  101. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, Nikiforov YE. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99:E276-85. [Crossref] [PubMed] [PMC] 
  102. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM. Patientspecific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366-1372. [PubMed] 
  103. Griffith OL, Melck A, Jones SJ, Wiseman SM. Metaanalysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol. 2006;24:5043-5051. [Crossref] [PubMed] 
  104. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436-7440. [Crossref] [PubMed] 
  105. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab. 1990; 70:830-835. [Crossref] [PubMed] 
  106. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587-1597.[Crossref]  [PubMed] 
  107. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-619. [Crossref] [PubMed] 
  108. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;14:1063-1075. [Crossref] [PubMed]